Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 10, 2010 - Issue 3
Submit an article Journal homepage
24
Views
0
CrossRef citations to date
0
Altmetric
Special Report

Implementing registries and results databases of clinical trials: is there a side effect?

Matthias Dahm Universitat Rovira i Virgili (URV), Reus, Spain; Universitat Rovira i Virgili (URV), Reus, Spain
,
Paula González Universidad Pablo de Olavide, Department of Economics, Carretera de Utrera km 1, 41013 Sevilla, Spain. [email protected]; Universidad Pablo de Olavide, Department of Economics, Carretera de Utrera km 1, 41013 Sevilla, Spain. [email protected]
&
Nicolás Porteiro Universidad Pablo de Olavide, Department of Economics, Carretera de Utrera km 1, 41013 Sevilla, Spain. [email protected]; Universidad Pablo de Olavide, Department of Economics, Carretera de Utrera km 1, 41013 Sevilla, Spain. [email protected]
Pages 247-251 | Published online: 09 Jan 2014

References

  • Sibbald B, Roland M. Understanding controlled trials: Why are randomised controlled trials important? BMJ316, 201 (1998).
  • Simes RJ. Clinical trials and “real-world” medicine [editorial]. Med. J. Aust.177, 410–411 (2002).
  • De Angelis C, Drazen JM, Frizelle FA et al. Clinical Trial Registration: a statement from the International Committee of Medical Journal Editors. Ann. Intern. Med.141, 477–478 (2004).
  • Dahm M, González P, Porteiro N. Trials, tricks and transparency: how disclosure rules affect clinical knowledge. J. Health Econ.28, 1141–1153 (2009).
  • Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a Phase IV study? Common clinical research designs, registries, and self-reporting systems. J. Clin. Pharmacol.47, 1074–1086 (2007).
  • Vlahakes GJ. The value of Phase 4 clinical testing. N. Engl. J. Med.354(4), 413–414 (2006).
  • Simes RJ. Publication bias: the case for an international registry of clinical trials. J. Clin. Oncol.4, 1529–1541 (1986).
  • Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al. “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.” N. Engl. J. Med.353, 2813–2814 (2005).
  • Harris G, Koli E. Lucrative drug, danger signals and the FDA. The New York Times, 10 June (2005).
  • Avorn J. Dangerous deception – hiding the evidence of adverse drug effects. N. Engl. J. Med.355(21), 2169–2171 (2006).
  • Harris G. Heart surgery drug pulled from market. The New York Times, 6 November (2007).
  • Berenson A. Cardiologists question delay of data on 2 drugs. The New York Times, 21 November (2007).
  • Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med.358(3), 252–260 (2008).
  • Krimsky S. Conflict of interest and cost-effectiveness analysis. JAMA282(15), 1474–1475 (1999).
  • Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp. Clin. Trials29, 109–113 (2008).
  • Davidoff F, De Angelis CD, Drazen JM et al.Sponsorship, authorship and accountability. N. Engl. J. Med.345(11), 825–826 (2001).
  • Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PT, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials. JAMA291, 2457–2465 (2004).
  • Milgrom P. Good news and bad news: representation theorems and applications. Bell J. Econ.12, 380–391 (1981).
  • Azoulay P. Do pharmaceutical sales respond to scientific evidence? J. Econ. Manage. Strat.11(4), 551–594 (2002).
  • De Angelis CD, Drazen JM, Frizelle FA et al. Is this clinical trial fully registered?: a statement from the International Committee of Medical Journal Editors. JAMA293, 2927–2929 (2005).
  • Laine C, Horton R, De Angelis CD. Clinical trial registration: looking back and moving ahead. N. Engl. J. Med.356, 2734–2736 177(1), 57 (2007).
  • Tse T, Williams RJ, Zarin DA. Reporting “basic results” in ClinicalTrials.gov. Chest136, 295–303 (2009).
  • Wood AJJ. Progress and deficiencies in the registration of clinical trials. N. Engl. J. Med.360, 824–830 (2009).
  • Zarin DH, Tse T, Ide NC. Trial registration at ClinicalTrials.gov between May and October 2005. N. Engl. J. Med.353(26), 2779–2787 (2005).
  • Sekeres M, Gold JL, Chan A-W et al. Poor reporting of scientific leadership information in clinical trial registries. PLoS ONE3(2), E1610 (2008).
  • Henry E. Strategic disclosure of research results: the cost of proving your honesty. Econ. J.119, 1036–1064 (2009).
  • Tufts Center for the Study of Drug Development. FDA requested postmarketing studies in 73% of recent new drug approvals. Impact Report6(4) (2004).
  • Folland S, Goodman AC, Stano M. The Economics of Health and Health Care. Pearson Prentice Hall, NJ, USA (2004).
  • Drazen MJ, Morrissey S, Curfman GD. Open clinical trials. N. Engl. J. Med.357(17), 1756–1757 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.